Corifact

Drug Overview

Corifact is a highly specialized, life-saving medication within the field of hematology. For patients living with a severe, rare genetic bleeding disorder, this medication acts as a vital safety net, allowing them to live without the constant fear of sudden, uncontrollable hemorrhage. Classified as a Coagulation Factor XIII (Human) replacement therapy, Corifact is a powerful Biologic derived directly from human plasma.

Before the development of targeted factor concentrates, patients missing this specific clotting protein had to rely on frequent, high-volume transfusions of fresh frozen plasma, which carried significant risks of fluid overload. Corifact provides a concentrated, precise dose of the exact protein these patients are missing, serving as a highly effective Targeted Therapy to stabilize their blood’s ability to clot.

• Generic Name: Coagulation Factor XIII (Human)
• US Brand Names: Corifact
• Drug Category: Hematology / Bleeding Disorders
• Drug Class: Coagulation Factor XIII (Human) / Antihemophilic Agent
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: FDA-approved for routine prophylactic (preventative) treatment and perioperative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Corifact works, you must look at the final stages of the body’s blood clotting process, known as the coagulation cascade. When a blood vessel is injured, a chain reaction of proteins creates a web made of a substance called fibrin to plug the hole. However, this initial fibrin web is weak and easily broken.

This is where Factor XIII plays its crucial role. Factor XIII acts as a “molecular glue.” In a healthy body, it is activated by another clotting enzyme (thrombin) at the very end of the cascade. Once activated, Factor XIII cross-links the weak fibrin strands, weaving them tightly together to create a tough, stable blood clot that stops the bleeding and allows the tissue underneath to heal.

Patients with congenital Factor XIII deficiency have a genetic mutation that prevents their bodies from producing enough of this “glue.” Because their blood clots break down almost as soon as they form, they are at an extreme risk for severe, delayed bleeding, including spontaneous bleeding into the brain, joints, and soft tissues. This deficiency is notoriously dangerous because standard blood clotting tests (like PT/INR and aPTT) often appear completely normal, masking the severity of the defect.

Corifact works by directly replacing the missing “glue.” It is a highly purified concentrate of human Factor XIII. When infused intravenously, this Biologic circulates in the patient’s bloodstream. When an injury occurs, the infused Factor XIII seamlessly integrates into the patient’s coagulation cascade, activating at the correct moment to cross-link the fibrin web, stabilizing the clot, and significantly reducing the risk of a life-threatening hemorrhage.

FDA-Approved Clinical Indications

Primary Indication

Corifact is specifically indicated for the routine prophylactic (preventative) treatment of congenital Factor XIII deficiency in adults and children. In this hematology category, it is used as a lifelong replacement therapy. By receiving regular, monthly infusions, patients maintain enough of the Factor XIII protein in their blood to prevent spontaneous bleeding episodes before they start, protecting their joints and vital organs from hemorrhage-induced damage. It is also approved for perioperative management, meaning it is given before surgery to ensure normal wound healing and prevent surgical bleeding.

Other Approved & Off-Label Uses

Because Corifact is a highly specific Targeted Therapy designed to replace one exact missing protein, its uses are very narrow.

• Approved: Congenital Factor XIII deficiency (Prophylaxis and Perioperative management).
• Off-Label: It is occasionally used off-label to manage acute, severe bleeding episodes in patients who have acquired Factor XIII deficiency (where the body’s immune system or another severe illness temporarily destroys or consumes the body’s natural Factor XIII), though this requires expert hematological supervision.

Dosage and Administration Protocols

Corifact is administered as an intravenous (IV) infusion. Because Factor XIII has a very long half-life in the blood compared to other clotting factors, the treatment schedule is typically once a month, which offers patients a highly manageable routine.

Important Adjustments:

• Dose Titration: If a patient experiences a breakthrough bleed while on the standard 40 IU/kg monthly dose, or if their trough levels (the lowest level of the drug in the blood just before the next dose) fall below the target of 10% to 20%, the physician may adjust the dose up to a maximum of 40 IU/kg every 21 days.
• Hepatic/Renal Insufficiency: There are no specific dose adjustments mandated for kidney or liver impairment, but physicians will monitor these patients closely.
• Weight-Based Dosing: Because the dose is calculated by weight (IU/kg), growing children and patients who experience significant weight changes must have their doses recalculated at regular intervals.

Clinical Efficacy and Research Results

Clinical research from 2020 to 2025 consistently supports the profound efficacy of Corifact in preventing life-threatening bleeds. In pivotal clinical trials evaluating its use for routine prophylaxis, the results were highly definitive.

Data shows that patients treated with the standard monthly dose of Corifact experienced a near-total elimination of spontaneous, severe bleeding events. The mean annualized bleeding rate (ABR) for spontaneous bleeds requiring treatment dropped to nearly zero. Furthermore, pharmacokinetic studies confirm that a monthly infusion successfully maintains target trough levels (above 10% activity) in the vast majority of patients, which is the critical threshold required to prevent severe hemorrhage and ensure normal clot stability.

Safety Profile and Side Effects

Black Box Warning

Corifact does not have an FDA Black Box Warning.

Common side effects (>10%)

Most patients tolerate this Biologic very well. When adverse reactions do occur, they are generally mild and may include:

• Headache
• Joint pain (arthralgia)
• Injection site reactions (mild pain, redness, or swelling where the IV was placed)
• Chills or mild fever during the infusion

Serious adverse events

• Hypersensitivity and Anaphylaxis: Because it is derived from human plasma, severe allergic reactions, including rash, hives, chest tightness, and difficulty breathing, can occur.
• Thromboembolic Events (VTE/Thrombosis): Because the drug strongly promotes clot stability, there is a theoretical risk of forming unwanted blood clots, especially if target factor levels are significantly overshot or if the patient has other cardiovascular risk factors.
• Neutralizing Antibodies (Inhibitors): The body’s immune system may mistakenly identify the infused protein as an invader and create antibodies against it. This neutralizes the drug, making it ineffective and instantly increasing the risk of severe bleeding.

Management Strategies

If a severe allergic reaction occurs during infusion, the administration must be stopped immediately, and emergency medical treatment (such as epinephrine and antihistamines) should be given. If a patient begins experiencing frequent breakthrough bleeds despite receiving their monthly dose, the hematologist will order a specific blood test to check for neutralizing antibodies. If antibodies are present, alternative bypassing therapies may be required. Furthermore, to mitigate the risk of transmitting blood-borne viruses (since the drug is made from pooled human plasma), the manufacturing process includes rigorous viral inactivation and filtration steps.

Research Areas

Current research in severe hematologic complications is exploring the broader biological roles of Factor XIII. Because Factor XIII is vital not only for blood clotting but also for tissue repair, cartilage growth, and maintaining pregnancy, researchers are investigating if maintaining higher baseline levels of Factor XIII can improve wound healing after major surgeries or trauma in patients without a congenital deficiency. Additionally, early-phase studies are exploring novel, longer-acting recombinant versions of Factor XIII that could eventually extend the time between infusions beyond 28 days.

Disclaimer: These studies regarding higher baseline Factor XIII levels for wound healing and longer-acting recombinant Factor XIII formulations are currently exploratory and are not yet applicable to routine clinical practice. The proposed benefits for patients without congenital deficiency, as well as any extension of dosing intervals beyond the established monthly regimen, remain unproven and should not be presented as standard or definitive therapy.

Patient Management and Practical Recommendations

Pre-treatment Tests

Before starting therapy, several baseline diagnostics are required:

• Factor XIII Activity and Antigen Assays: To confirm the severe deficiency (usually less than 1% to 5% activity).
• Clot Solubility Test: A specialized test used because standard PT/INR and aPTT tests will appear completely normal in these patients.
• Viral Screening: Baseline testing for Hepatitis B, C, and HIV is standard practice before starting any plasma-derived therapy.

Precautions during treatment

• Monitor for Clots: Patients and providers must be vigilant for signs of deep vein thrombosis (DVT) or pulmonary embolism, such as sudden leg swelling, chest pain, or shortness of breath.
• Track Bleeding: Patients should monitor for any unusual bruising, prolonged bleeding from minor cuts, or severe headaches, which could indicate the development of neutralizing antibodies.

“Do’s and Don’ts” List

• DO keep a precise calendar of your infusion dates. Consistency is the absolute key to preventing breakthrough bleeds.
• DO wear a medical alert bracelet stating you have Congenital Factor XIII deficiency and require specific replacement therapy.
• DO maintain a detailed log of any minor or major bleeding events to share with your hematologist.
• DON’T take over-the-counter NSAIDs (like aspirin, ibuprofen, or naproxen) without consulting your doctor, as these medications interfere with platelet function and increase bleeding risk.
• DON’T skip doses even if you feel perfectly healthy; the medication prevents bleeds before they start.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. The information provided in this guide is not intended to diagnose, treat, cure, or prevent any disease without the direct supervision of a licensed physician. Always consult your hematologist or healthcare team regarding your specific medical condition, treatment options, and any side effects you may experience.